{
    "ticker": "ABVX",
    "name": "Abivax SA",
    "description": "Abivax SA is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of inflammatory diseases and viral infections. Founded in 2013 and headquartered in Paris, France, Abivax aims to leverage its proprietary technology to create novel therapeutic approaches that can significantly improve patient outcomes. The company's lead product candidate, ABX464, is an oral treatment designed to address inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. By targeting the underlying mechanisms of inflammation, ABX464 has the potential to provide a safer and more effective treatment option compared to existing therapies. In addition to its focus on inflammatory diseases, Abivax is also exploring the use of ABX464 in the context of HIV treatment, demonstrating its versatility in addressing multiple health challenges. With a strong pipeline and a commitment to scientific excellence, Abivax is well-positioned to make significant advances in the biotech sector while improving the lives of patients suffering from chronic conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Paris, France",
    "founded": "2013",
    "website": "https://www.abivax.com",
    "ceo": "Philippe Pouletty",
    "social_media": {
        "twitter": "https://twitter.com/abivax",
        "linkedin": "https://www.linkedin.com/company/abivax/"
    },
    "investor_relations": "https://www.abivax.com/investors/",
    "key_executives": [
        {
            "name": "Philippe Pouletty",
            "position": "CEO"
        },
        {
            "name": "Aur\u00e9lien J. M. Thibault",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ABX464"
            ]
        }
    ],
    "seo": {
        "meta_title": "Abivax SA | Innovative Biotechnology Solutions",
        "meta_description": "Explore Abivax SA, a biotechnology company focused on developing novel therapies for inflammatory diseases and viral infections. Learn more about our pipeline and mission.",
        "keywords": [
            "Abivax",
            "Biotechnology",
            "Inflammatory Diseases",
            "ABX464",
            "Chronic Conditions",
            "HIV Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Abivax known for?",
            "answer": "Abivax is known for developing innovative therapies for inflammatory diseases and viral infections, particularly its lead product ABX464."
        },
        {
            "question": "Who is the CEO of Abivax?",
            "answer": "Philippe Pouletty is the CEO of Abivax SA."
        },
        {
            "question": "Where is Abivax headquartered?",
            "answer": "Abivax is headquartered in Paris, France."
        },
        {
            "question": "What is ABX464?",
            "answer": "ABX464 is Abivax's lead product candidate aimed at treating inflammatory bowel diseases and has potential applications in HIV treatment."
        },
        {
            "question": "When was Abivax founded?",
            "answer": "Abivax was founded in 2013."
        }
    ],
    "competitors": [
        "MRNA",
        "BMRN",
        "NVS",
        "GILD"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "AMGN",
        "VRTX"
    ]
}